Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting

Lauren Greenberg*, Lene Ryom, Bastian Neesgaard, Jose M. Miró, Line Dahlerup Rasmussen, Robert Zangerle, Katharina Grabmeier-Pfistershammer, Huldrych F. Günthard, Katharina Kusejko, Colette Smith, Cristina Mussini, Marianna Menozzi, Ferdinand Wit, Marc Van Der Valk, Antonella D'Arminio Monforte, Stcrossed D.Sign©phane De Wit, Coca Necsoi, Annegret Pelchen-Matthews, Jens Lundgren, Lars PetersAntonella Castagna, Camilla Muccini, Jörg Janne Vehreschild, Christian Pradier, Andreu Bruguera Riera, Anders Sönnerborg, Kathy Petoumenos, Harmony Garges, Felipe Rogatto, Nikos Dedes, Loveleen Bansi-Matharu, Amanda Mocroft, RESPOND Study Group

*Kontaktforfatter

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

5 Downloads (Pure)

Abstrakt

Background: Limited data exist examining the association between incident cancer and cumulative integrase inhibitor (INSTI) exposure. Methods: Participants were followed from baseline (latest of local cohort enrollment or January 1, 2012) until the earliest of first cancer, final follow-up, or December 31, 2019. Negative binomial regression was used to assess associations between cancer incidence and time-updated cumulative INSTI exposure, lagged by 6 months. Results: Of 29 340 individuals, 74% were male, 24% were antiretroviral treatment (ART)-naive, and median baseline age was 44 years (interquartile range [IQR], 36-51). Overall, 13 950 (48%) individuals started an INSTI during follow-up. During 160 657 person-years of follow-up ([PYFU] median 6.2; IQR, 3.9-7.5), there were 1078 cancers (incidence rate [IR] 6.7/1000 PYFU; 95% confidence interval [CI], 6.3-7.1). The commonest cancers were non-Hodgkin lymphoma (n=113), lung cancer (112), Kaposi's sarcoma (106), and anal cancer (103). After adjusting for potential confounders, there was no association between cancer risk and INSTI exposure (≤6 months vs no exposure IR ratio: 1.15 [95% CI, 0.89-1.49], >6-12 months; 0.97 [95% CI, 0.71-1.32], >12-24 months; 0.84 [95% CI, 0.64-1.11], >24-36 months; 1.10 [95% CI, 0.82-1.47], >36 months; 0.90 [95% CI, 0.65-1.26] [P=.60]). In ART-naive participants, cancer incidence decreased with increasing INSTI exposure, mainly driven by a decreasing incidence of acquired immune deficiency syndrome cancers; however, there was no association between INSTI exposure and cancer for those ART-experienced (interaction P<.0001). Conclusions: Cancer incidence in each INSTI exposure group was similar, despite relatively wide CIs, providing reassuring early findings that increasing INSTI exposure is unlikely to be associated with an increased cancer risk, although longer follow-up is needed to confirm this finding.

OriginalsprogEngelsk
Artikelnummerofac029
TidsskriftOpen Forum Infectious Diseases
Vol/bind9
Udgave nummer3
Antal sider11
ISSN2328-8957
DOI
StatusUdgivet - mar. 2022

Bibliografisk note

Publisher Copyright:
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Fingeraftryk

Dyk ned i forskningsemnerne om 'Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting'. Sammen danner de et unikt fingeraftryk.

Citationsformater